FORMULATION OF CIPROFLOXACIN HYDROCHLORIDE LOADED BIODEGRADABLE NANOPARTICLES: OPTIMIZATION OF THE FORMULATION VARIABLES.
The aim of this work was to formulate nanoparticles with longer sustainment since it can play an important role in treatment of chronic osteomyelitis. A factorial design 23 was used to optimize the formulation variables of ciprofloxacin hydrochloride (CP) loaded biodegradable nanoparticles (NPS). The effect of three independent variables, namely; the polymer type (Poly D, L-lactide-co-glycolide 50/50& Poly (D, L-lactide), the polymer molecular weight(M.Wt) and the drug to polymer ratio on the particle size, encapsulation efficiency (EE%), zeta potential and the time required for 90% of ciprofloxacin to be released (t90%) was investigated . The selected drug loaded nanoparticles was subjected to further investigations including; Scanning electron microscope (SEM), DSC, x-ray powder diffractometry and FTIR spectroscopy. Moreover the antimicrobial effectiveness of the selected formula was investigated. The results revealed that the mean particle size ranged from 180-355 nm while the EE% ranged from 52-70%. The selected formula retained its antimicrobial activity throughout the preparation process.
A validated RP-HPLC method for simultaneous determination of Metformin HCl, Pioglitazone HCl and Glimepiride in pharmaceutical formulation
In the present scenario, most commonly attacking disease is diabetes. Recent studies indicate that prevalence of type-2 diabetes is rapidly increasing in the society due to life style changes. Type-2 diabetes is a progressive disorder with reduced insulin level, increased blood glucose level with a consistent and steady increase in glycosylated hemoglobin (HbA1C) overtime associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. Pathophysiologic abnormalities associated with type-2 diabetes are: (i) impaired insulin secretion, (ii) excessive hepatic glucose output, and (iii) insulin resistance in skeletal muscles, liver and adipose tissue. These defects have been treated by use of oral insulin secretagogues (sulphonyl ureas/glinides) or insulin, biguanides, and thiazolidinediones, respectively.